Login    Join free Add to favorites    中文
home > news > Illumina Applauds FDA鈥檚 Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Illumina Applauds FDA鈥檚 Issuance of Draft Guidances to Advance Precision Medicine Using Next Generation Sequencing

hits:565     Date:07/08/16
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that it supports the Food and Drug Administration (FDA) in their efforts to provide a flexible and streamlined approach to the oversight of next generation sequencing (NGS) diagnostic tests, as represented by FDA鈥檚 release of two new draft guidance documents. The FDA draft guidances are part of the larger Precision Medicine Initiative announced by President Obama in his 2015 State of the Union address.
 
鈥淭his is an important step forward,鈥 said Francis deSouza, President and CEO of Illumina. 鈥淲e support the proactive actions the FDA is taking to recognize the benefits of next generation sequencing and provide appropriately flexible and adaptive regulatory oversight of these tests, while accommodating the rapid evolution of NGS technologies.鈥
 
Next generation sequencing can examine millions of DNA variants at a time, reading a patient鈥檚 DNA to detect genomic variations that determine whether a person has or is at risk of disease and informing treatment decisions. Illumina will continue to partner with customers and work with FDA to collectively enable the promise of genetic medicine by driving the adoption of next generation sequencing.
 
 
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Related News>> more
advertisement

Copyright(C) 2006-2017 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙